Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients-Reference-Cited by-同舟云学术

Measurement of the hepatitis B core-related antigen is valuable for predicting the pathological status of liver tissues in chronic hepatitis B patients

Published:2016-09 Issue: Volume:235 Page:92-98
ISSN:0166-0934
Container-title:Journal of Virological Methods
language:en
Short-container-title:Journal of Virological Methods

Author:

Zhang Zhan-Qing,Lu Wei,Wang Yan-Bing,Weng Qi-Cheng,Zhang Zhi-Yong,Yang Zhi-Qiang,Feng Yan-Ling

Publisher

Elsevier BV

Subject

Virology

Reference32 articles.

1. Evaluation of normal or minimally elevated alanine transaminase: age and DNA level in predicting liver histological changes in chronic hepatitis B;Alam;Liver Int.,2011

2. 2014: Non-invasive assessment of liver fibrosis in chronic hepatitis B;Branchi;World J. Gastroenterol.,2014

3. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers;Brunetto;Gastroenterology,2010

4. A longitudinal study on the natural history of serum hepatitis b surface antigen changes in chronic hepatitis B;Chan;Hepatology,2010

5. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management;Chang;J. Hepatol.,2014

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A critique and systematic review of the clinical utility of hepatitis B core-related antigen;Journal of Hepatology;2023-04

2. Serum HBsAg and HBcrAg is associated with inflammation in HBeAg-positive chronic hepatitis B patients;Frontiers in Cellular and Infection Microbiology;2023-03-31

3. Noninvasive assessments of liver disease severity based on biomarkers;Comprehensive Guide to Hepatitis Advances;2023

4. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral;Viruses;2022-11-29

5. Moving towards core antigen for the management of patients with overt and occult HBV infection;Panminerva Medica;2021-12